Loading…

microRNA-125a targets MAVS and TRAF6 to modulate interferon signaling and promote HCV infection

•HCV infection promotes miR-125a upregulation.•miR-125a targets MAVS and TRAF6 and thereby compromises type I IFN responses to HCV.•miR-125a facilitates the replication of HCV. Hepatitis C virus (HCV) can cause chronic lifelong infections in humans, resulting in sustained hepatic inflammation, liver...

Full description

Saved in:
Bibliographic Details
Published in:Virus research 2021-04, Vol.296, p.198336-198336, Article 198336
Main Authors: Yan, Jianguo, Zhang, Yuting, Su, Yan, Tian, Linlin, Qin, Peifang, Xu, Xingfeng, Zhou, Yali
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•HCV infection promotes miR-125a upregulation.•miR-125a targets MAVS and TRAF6 and thereby compromises type I IFN responses to HCV.•miR-125a facilitates the replication of HCV. Hepatitis C virus (HCV) can cause chronic lifelong infections in humans, resulting in sustained hepatic inflammation, liver cirrhosis, and hepatocellular carcinoma. The clearance of HCV infections is dependent upon effective and coordinated innate and adaptive antiviral immune responses. However, HCV has evolved a range of strategies that enable it to evade or overcome the host immune response, enabling the virus to persist in susceptible hosts through mechanisms that remain to be fully clarified. Herein, we describe a novel mechanism whereby HCV can evade immune surveillance by activating microRNA (miR)-125a. Hepatocytes upregulate miR-125a following HCV infection, and serum from HCV-infected patients similarly exhibits the upregulation of this miRNA. We found that miR-125a is able to target and suppress the expression of two key genes associated with the interferon (IFN) signaling pathway - mitochondrial antiviral signaling (MAVS) and TNF receptor-associated factor 6 (TRAF6). Disrupting the expression of these genes can in turn compromise type I IFN responses to HCV. Together, our data reveal that HCV infection results in the upregulation of miR-125a, which negatively regulates IFN signaling via inhibiting the expression of MAVS and TRAF6, thereby enabling the virus to evade innate antiviral immunity. Targeting this pathway may thus represent an efficient approach to treating HCV and bolstering antiviral immune responses in infected patients.
ISSN:0168-1702
1872-7492
DOI:10.1016/j.virusres.2021.198336